Ph3 study of TAR-210 with high risk participants with Bladder Cancer

A Phase 3 Randomized Open-label Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gu�rin (BCG) Protocol number: 42756493BLC3005